Journals / Türk Kardiyoloji Derneği Arşivi / 2000 / Cilt: 28 - Sayı: 9

The effect of lipoprotein(a) to thrombolytic therapy and spontaneous reperfusion in acute myocardial infarction: A comparative study

Akut miyokard infarktüsünde lipoprotein(a)'nın trombolitik tedavi ve spontan reperfüzyona etkisinin karşılaştırılması

Pages
543–547
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, in MI patients with- out use of parenteral TT, spontaneous reperfusion rate was found significantly higher in cases with low Lp(a) level compared to those with high Lp(a) level.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although lipoprotein-(a) [Lp(a)] is a known risk factor in acute myocardial infarction (MI), no sufficient data are available on the question is affected by Lp(a) levels the outcome of patients undergoing thrombolytic therapy (TT).
📊
Key Findings & Data:The aim of this study was to evaluate the role of serum Lp(a) levels on the outcome of the infarct-related artery in the use of TT following acute MI. 78 patients were randomly allocated into 3 groups.
💡
Conclusion & Impact:However, in MI patients with- out use of parenteral TT, spontaneous reperfusion rate was found significantly higher in cases with low Lp(a) level compared to those with high Lp(a) level.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although lipoprotein-(a) [Lp(a)] is a known risk factor in acute myocardial infarction (MI), no sufficient data are available on the question is affected by Lp(a) levels the outcome of patients undergoing thrombolytic therapy (TT). The aim of this study was to evaluate the role of serum Lp(a) levels on the outcome of the infarct-related artery in the use of TT following acute MI. 78 patients were randomly allocated into 3 groups. Group A consisted of 18 patients who received 1.5 million IU streptokinase (intravenously), Group B; 38 cases receiving 100 mg t-PA totally (intravenously) and Group C; 22 cases who did not receive any TT as a control group. All cases had undergone coronary angiography in the first 7 days and the degree of TIMI flow was determined in the infarct-related artery with TIMI-0 and I being considered as unsuccessful perfusion, whereas TIMI-II and III as successful. Lp(a) level ? 30 mg/dl was considered as high Lp(a) level. No significant difference was found between Group A and B patients, in cases with high or low Lp(a) levels in respect to patency rates (p>0,05 for both). In Group C however, patency rate had been found significantly higher in cases with high Lp(a) level compared to cases with low Lp(a) (p0.05). The time interval from acute MI to coronary angiography was similar in all groups (p>0.05 for all). Conclusion: Lp(a) level in cases with MI does not affect the reperfusion outcome of parenteral thrombolytic agents. However, in MI patients with- out use of parenteral TT, spontaneous reperfusion rate was found significantly higher in cases with low Lp(a) level compared to those with high Lp(a) level.

Özet

Akut miyokard infarktüsünde (MI) lipoprpotein-a'nın [Lp(a)] bir risk faktörü olduğu bilinmesine rağmen, trombolitik tedavi(TT) alan ve almayan hastalardaki etkisi ve mekanizması hakkında bilgilerimiz yeterli değildir. Çalışmamızın amacı TT alan ve almayan hastalarda Lp(a)'nın trombolizis rolünü karşılaştırmaktır. Bu amaçla çalışmaya alınan 78 vaka üç grupta incelendi. Grup-A; 1.5 milyon Ü intravenöz streptokinaz uygulanan 18, Grup-B; total 100 mg intravenöz doku-tipi plasminogen aktivatörü (t-PA) uygulanan 38 ve TT uygulanmayan 22 vaka çalışmaya alındı. Bütün vakalara ilk 7 gün içerisinde koroner anjiyografi uygulanarak, infarktla ilişkili koroner arterin MI'da trombolizis (TIMI) akım derecesi tespit edildi. TIMI-0 ve I başarısız, TIMI-II ve III başarılı perfüzyon olarak değerlendirildi. Lp(a)'nın >30 mg/dl olması yüksek olarak kabul edildi. Grup-A ve B hastalarında, Lp(a) seviyesi yüksek ve düşük olanlardaki patensi oranları arasında anlamlı fark bulunmadı (her ikisi için p>0.05). Grup-C hastalarında Lp(a) seviyesi düşük olanlarda, yüksek olanlara göre patensi oranı anlamlı olarak daha yüksek bulundu (p0.05). Grup-A,B ve C hastalarında, ayrıca Grup-C hastalarından Lp(a) seviyesi düşük ve yüksek olanlar arasında koroner anjiyografi uygulanma süreleri bakımından anlamlı farklılık yoktu (hepsi için p>0.05). Sonuç: Lp(a) seviyesi akut MI vakalarında dışardan verilen trombolitik ajanların (streptokinaz ve t-PA) reperfüzyon sonucunu etkilememektedir. Bununla beraber dışardan trombolitik ajan almayan Akut MI vakalarında Lp(a) seviyesi düşük olanlarda, olmayanlara göre spontan reperfüzyon alamlı olarak daha fazla bulunmuştur.

🔖

Cite This Article

DAĞDELEN, S., EREN, N., AKDEMİR, İ., ÇAĞLAR, N., ERGELEN, M., YILDIZ, M., KARABULUT, H. (2022). The effect of lipoprotein(a) to thrombolytic therapy and spontaneous reperfusion in acute myocardial infarction: A comparative study. Türk Kardiyoloji Derneği Arşivi, Cilt: 28 - Sayı: 9, 543–547. https://ajindex.com/articles/634117

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. GISSI Study Group. Effectiveness of intravenous thrombolytic treatment İn acut myocardial infarction. Lancet 1986
  2. I:397-401 2. ISIS 2 (Second International Study of Infarct Survival Colloboralive Group). Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected myocardial infarction. Lancet 1988
  3. II:349-60 3. Cesebro JH, Knatterud G, Roberts R, et al: Throm-bolysis in myocardial infarction (TIMI) trial phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987
  4. 54 4. Van der Werf F, Arnold AER: For the European Cooperative Study Group for recombinant tissue plasminogen activator. Intravenous tissue plasminogen activator and the size of infarcts, left ventricular function and survival İn acute myocardial infarction. BMJ 1988
  5. 13G4-79 5. White HD, Norris RM, Brown MA, et ah Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Medl987
  6. 5 6. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: a preliminary report of a plasebo-controlled clinical trial. Lancet 1988
  7. I:545-9 7. ISIS 3: A randomised comparison of streptokinase versus tissue plasminogen activator versus anistreplase and aspirin plus heparin versus aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1991
  8. 70 8. Durrington PN, Isliola M, Hunt L, Arrol S, Blıatna-ger D: Apolipoprotein (a), AI and B and parental history in men with early onset ischeamic heart disease. Lancet 1988:1:1070-3 9. Tokgözoğlu SL, Ozmen F, Kabukçu M, et al: Doesinreascd liporpotein(a) impair the effectiveness of thorom-bolysis with streptokinase?.Angiology 1995
  9. 8,727-31 10. Kostner GM,Avogaro P,CazzoIata G, Marth E, Bit-tolo-Bon G,Quinci GB: Lipoprotein (a) and the risk for myocardial infarction. Atherosclerosis 1981
  10. 61 11. Dahlen GH, Guyton JR, Attar M, Farmer JA, Ka-utz JA, Gotto AM: Association of levels of Hpoprote-in(a), plasma lipids and other lipoproteins with coronary artery disease documanted by angiography. Circulation 1986
  11. 65 12. Uterman G: The mysteries of Hpoprotein(a). Science 1989:246:904-10. 13. Is Iİpoprotein(a) an independent risk factor for ische-mic heart disease in men? The Quebec cardiovaascular study. J Am Coll Cardiol. 1998:31:3,519-25 14. Miles LA, Plow EF: Lp(a)
  12. An İnterpoler with the fib-rinolytic sy